By Peter Orengo
Three leaders in malaria vaccine development have announced a collaboration to evaluate a potential vaccine candidate designed to prevent transmission of malaria from mosquitoes to humans.
Path Malaria Vaccine Initiative (MVI), National Institute of Allergy and Infectious Diseases (Niaid) and the John Hopkins Bloomberg School of Public Health Centre for Immunisation Research say protein Pfs25 vaccine could contribute to the eventual eradication of malaria.
The partners intend to conduct clinical trials in healthy adults to assess their safety.
The new partnership was announced at a presentation of the 60th annual meeting of the American Society of Tropical Medicine and Hygiene.
"Pfs25 is one of the transmission blocking vaccine (TBV) approaches that aim to block transmission of malaria from mosquitoes to humans by preventing the malaria parasite from developing in the mosquito," said Ashley Birkett, director of research and development at MVI.
Reduce pressure
While such vaccines would not directly protect an immunised individual from developing clinical malaria, they would reduce chances that other individuals in the community get malaria by preventing the spread of infection by the mosquito. Malaria kills nearly 800,000 people per year, most of them children under age five in Africa.
While drugs and insecticides have had a significant impact on fighting the disease, resistance of mosquitoes pose challenges.
TBV would work in synergy with the interventions, since blocking transmission of the parasite would reduce the pressure on other measures, thereby slowing the development of resistance and thus extending their effectiveness.
City Stars survive relegation (swa)